Registry-based study on the effect and safety of Firehawk™and Firehawk Liverty™ stent for coronary atherosclerotic lesions
Not Applicable
Recruiting
- Conditions
- Diseases of the circulatory system
- Registration Number
- KCT0006491
- Lead Sponsor
- Seoul National University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Over 19 years of age who has been treated with a Firehawk™ and Firehawk Liverty™ stent for coronary artery disease who has agreed in writing to participate in this registry study
Exclusion Criteria
There is no exclusion criteria in this study.
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method combined clinical events of Death, Myocardial infarction and Target Vessel Revascularization(TVR)
- Secondary Outcome Measures
Name Time Method cardiogenic death;myocardial infarction;stent thrombosis;bleeding events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of sirolimus-eluting stents in coronary atherosclerosis treatment?
How does the Firehawk™ stent compare to other drug-eluting stents in treating complex coronary lesions?
Which biomarkers are associated with optimal outcomes for patients receiving Firehawk Liverty™ stents?
What adverse events are commonly reported with Firehawk™ stents in long-term observational studies?
Are there combination therapies or competitor drugs that enhance sirolimus efficacy in coronary artery disease?